123 related articles for article (PubMed ID: 36509758)
1. Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer.
Adua SJ; Arnal-Estapé A; Zhao M; Qi B; Liu ZZ; Kravitz C; Hulme H; Strittmatter N; López-Giráldez F; Chande S; Albert AE; Melnick MA; Hu B; Politi K; Chiang V; Colclough N; Goodwin RJA; Cross D; Smith P; Nguyen DX
Nat Commun; 2022 Dec; 13(1):7690. PubMed ID: 36509758
[TBL] [Abstract][Full Text] [Related]
2. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
[TBL] [Abstract][Full Text] [Related]
3. Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.
Li XF; Shen WZ; Jin X; Ren P; Zhang J
Sci Rep; 2020 Jul; 10(1):11236. PubMed ID: 32641854
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
5. Targeting S100A9-ALDH1A1-Retinoic Acid Signaling to Suppress Brain Relapse in EGFR-Mutant Lung Cancer.
Biswas AK; Han S; Tai Y; Ma W; Coker C; Quinn SA; Shakri AR; Zhong TJ; Scholze H; Lagos GG; Mela A; Manova-Todorova K; de Stanchina E; Ferrando AA; Mendelsohn C; Canoll P; Yu HA; Paik PK; Saqi A; Shu CA; Kris MG; Massague J; Acharyya S
Cancer Discov; 2022 Apr; 12(4):1002-1021. PubMed ID: 35078784
[TBL] [Abstract][Full Text] [Related]
6. Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients.
Chen J; Facchinetti F; Braye F; Yurchenko AA; Bigot L; Ponce S; Planchard D; Gazzah A; Nikolaev S; Michiels S; Vasseur D; Lacroix L; Tselikas L; Nobre C; Olaussen KA; Andre F; Scoazec JY; Barlesi F; Soria JC; Loriot Y; Besse B; Friboulet L
Ann Oncol; 2022 Apr; 33(4):434-444. PubMed ID: 35066105
[TBL] [Abstract][Full Text] [Related]
7. Real-world data on treatment outcomes in
Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
[TBL] [Abstract][Full Text] [Related]
8. YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer.
Yun J; Hong MH; Kim SY; Park CW; Kim S; Yun MR; Kang HN; Pyo KH; Lee SS; Koh JS; Song HJ; Kim DK; Lee YS; Oh SW; Choi S; Kim HR; Cho BC
Clin Cancer Res; 2019 Apr; 25(8):2575-2587. PubMed ID: 30670498
[TBL] [Abstract][Full Text] [Related]
9. P21-activated kinase 2-mediated β-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer.
Yi Y; Li P; Huang Y; Chen D; Fan S; Wang J; Yang M; Zeng S; Deng J; Lv X; Luo K; He Z; Liu H
Oncogene; 2022 Sep; 41(37):4318-4329. PubMed ID: 35986102
[TBL] [Abstract][Full Text] [Related]
10. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer.
Cai X; Miao J; Sun R; Wang S; Molina-Vila MA; Chaib I; Rosell R; Cao P
Pharmacol Res; 2021 Aug; 170():105701. PubMed ID: 34087353
[TBL] [Abstract][Full Text] [Related]
11. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
[TBL] [Abstract][Full Text] [Related]
12. Osimertinib for
Xie L; Nagpal S; Wakelee HA; Li G; Soltys SG; Neal JW
Oncologist; 2019 Jun; 24(6):836-843. PubMed ID: 30126856
[TBL] [Abstract][Full Text] [Related]
13. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S
Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930
[TBL] [Abstract][Full Text] [Related]
14. Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients.
Yang Z; Yang N; Ou Q; Xiang Y; Jiang T; Wu X; Bao H; Tong X; Wang X; Shao YW; Liu Y; Wang Y; Zhou C
Clin Cancer Res; 2018 Jul; 24(13):3097-3107. PubMed ID: 29506987
[No Abstract] [Full Text] [Related]
15. Osimertinib Induces the Opposite Effect of Proliferation and Migration in the Drug Resistance of EGFR-T790M Non-small Cell Lung Cancer Cells.
Wang RH; Chang CJ; Chen CH; Liu KK; Chao JI
Anticancer Agents Med Chem; 2023; 23(11):1309-1319. PubMed ID: 36815658
[TBL] [Abstract][Full Text] [Related]
16. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in
Okura N; Nishioka N; Yamada T; Taniguchi H; Tanimura K; Katayama Y; Yoshimura A; Watanabe S; Kikuchi T; Shiotsu S; Kitazaki T; Nishiyama A; Iwasaku M; Kaneko Y; Uchino J; Uehara H; Horinaka M; Sakai T; Tanaka K; Kozaki R; Yano S; Takayama K
Clin Cancer Res; 2020 May; 26(9):2244-2256. PubMed ID: 31953310
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP).
Cardona AF; Ruiz-Patiño A; Recondo G; Martín C; Raez L; Samtani S; Minata JN; Blaquier JB; Enrico D; Burotto M; Ordóñez-Reyes C; Chamorro DF; Garcia-Robledo JE; Corrales L; Zatarain-Barrón ZL; Más L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Mejía S; Jaller E; Vargas C; Carranza H; Otero J; Rodríguez J; Archila P; Bermudez M; Gamez T; Cordeiro de Lima V; Freitas H; Russo A; Polo C; Malapelle U; Perez DM; Rolfo C; Viola L; Rosell R; Arrieta O
Clin Lung Cancer; 2022 Sep; 23(6):522-531. PubMed ID: 35798634
[TBL] [Abstract][Full Text] [Related]
18. Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer.
Ichihara E; Hotta K; Ninomiya K; Kubo T; Ohashi K; Rai K; Tanaka H; Tabata M; Maeda Y; Kiura K
Lung Cancer; 2019 Jun; 132():54-58. PubMed ID: 31097094
[TBL] [Abstract][Full Text] [Related]
19. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.
Taniguchi H; Yamada T; Wang R; Tanimura K; Adachi Y; Nishiyama A; Tanimoto A; Takeuchi S; Araujo LH; Boroni M; Yoshimura A; Shiotsu S; Matsumoto I; Watanabe S; Kikuchi T; Miura S; Tanaka H; Kitazaki T; Yamaguchi H; Mukae H; Uchino J; Uehara H; Takayama K; Yano S
Nat Commun; 2019 Jan; 10(1):259. PubMed ID: 30651547
[TBL] [Abstract][Full Text] [Related]
20. A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R.
Makimoto G; Ninomiya K; Kubo T; Sunami R; Kato Y; Ichihara E; Ohashi K; Rai K; Hotta K; Tabata M; Maeda Y; Kiura K
Jpn J Clin Oncol; 2021 May; 51(6):956-965. PubMed ID: 33829270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
